Literature DB >> 15308734

Immunomodulatory effects of inactivated parapoxvirus ovis (ORF virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells.

Astrid Friebe1, Angela Siegling, Sonja Friederichs, Hans-Dieter Volk, Olaf Weber.   

Abstract

Inactivated parapoxvirus ovis (Orf virus; PPVO) recently displayed strong immunostimulating and modulating capacities in several animal models for acute and chronic virus infections through the induction of gamma interferon (IFN-gamma) as a key mediator of antiviral activity. The data presented in this work demonstrate that inactivated PPVO has strong effects on cytokine secretion by human immune cells, including the upregulation of inflammatory and Th1-related cytokines (IFN-gamma, tumor necrosis factor alpha [TNF-alpha], interleukin 6 [IL-6], IL-8, IL-12, and IL-18) as well as anti-inflammatory and Th2-related cytokines (IL-4, IL-10, and IL-1 receptor antagonist [IL-1ra]). Studies on the mechanism of action revealed virus particles to be the effective components of the preparation. The virus particles activate monocytes or other antigen-presenting cells (APC), e.g., plasmacytoid dendritic cells, through signaling over CD14 and a Toll-like receptor and the intracellular presence of certain PPVO-specific components. The activation of monocytes or APC is followed by the release of early proinflammatory cytokines (TNF-alpha, IL-6, and IL-8) as well as the Th1-related cytokines IL-12 and IL-18. Both IL-18 and IL-12 are involved in PPVO-mediated IFN-gamma release by T cells and/or NK cells. The proinflammatory response is accompanied by the induction of anti-inflammatory and Th2-related cytokines (IL-4, IL-10, and IL-1ra), which exert a limiting efffect on the inflammatory response induced by PPVO. We conclude that the induction of a natural immune response with physiologically significant amounts of different cytokines and with antiviral potential might provide advantages over existing antiviral immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308734      PMCID: PMC506965          DOI: 10.1128/JVI.78.17.9400-9411.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  Consequences of bacterial CpG DNA-driven activation of antigen-presenting cells.

Authors:  T Sparwasser; G B Lipford
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

Review 2.  Mechanism of action of CpG DNA.

Authors:  A M Krieg; G Hartmann; A K Yi
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

Review 3.  Macrophage activation by immunostimulatory DNA.

Authors:  K J Stacey; D P Sester; M J Sweet; D A Hume
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

Review 4.  Immunomodulation by virulence proteins of the parapoxvirus orf virus.

Authors:  D M Haig; S Fleming
Journal:  Vet Immunol Immunopathol       Date:  1999-12-15       Impact factor: 2.046

Review 5.  Subversion and piracy: DNA viruses and immune evasion.

Authors:  D M Haig
Journal:  Res Vet Sci       Date:  2001-06       Impact factor: 2.534

Review 6.  Roles of Toll-like receptors in innate immune responses.

Authors:  K Takeda; S Akira
Journal:  Genes Cells       Date:  2001-09       Impact factor: 1.891

Review 7.  Sequence and functional analysis of a homolog of interleukin-10 encoded by the parapoxvirus orf virus.

Authors:  S B Fleming; D M Haig; P Nettleton; H W Reid; C A McCaughan; L M Wise; A Mercer
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

Review 8.  Natural killer cells in antiviral defense: function and regulation by innate cytokines.

Authors:  C A Biron; K B Nguyen; G C Pien; L P Cousens; T P Salazar-Mather
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

9.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

10.  Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens.

Authors:  N Kadowaki; S Ho; S Antonenko; R W Malefyt; R A Kastelein; F Bazan; Y J Liu
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

View more
  19 in total

1.  Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman® low density immune arrays.

Authors:  Ann L Oberg; Neelam Dhiman; Diane E Grill; Jenna E Ryan; Richard B Kennedy; Gregory A Poland
Journal:  J Immunol Methods       Date:  2011-01-28       Impact factor: 2.303

2.  ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.

Authors:  Julia L Rintoul; Chantal G Lemay; Lee-Hwa Tai; Marianne M Stanford; Theresa J Falls; Christiano T de Souza; Byram W Bridle; Manijeh Daneshmand; Pamela S Ohashi; Yonghong Wan; Brian D Lichty; Andrew A Mercer; Rebecca C Auer; Harold L Atkins; John C Bell
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

3.  A novel inhibitor of the NF-{kappa}B signaling pathway encoded by the parapoxvirus orf virus.

Authors:  D G Diel; G Delhon; S Luo; E F Flores; D L Rock
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  Conventional bone marrow-derived dendritic cells contribute to toll-like receptor-independent production of alpha/beta interferon in response to inactivated parapoxvirus ovis.

Authors:  Sabine Siegemund; Andrea Hartl; Heiner von Buttlar; Franziska Dautel; Rüdiger Raue; Marina A Freudenberg; György Fejer; Mathias Büttner; Gabriele Köhler; Carsten J Kirschning; Tim Sparwasser; Gottfried Alber
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

5.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

6.  Orally administered β-glucan improves the hemolytic activity of the complement system in horses.

Authors:  Taline Scalco Picetti; Lucas de Figueiredo Soveral; Rovian Miotto; Luana Marina Scheer Erpen; Yasmin Kreutz; João Antônio Guizzo; Rafael Frandoloso; Luiz Carlos Kreutz
Journal:  Vet World       Date:  2021-04-05

7.  Novel immune-modulator identified by a rapid, functional screen of the parapoxvirus ovis (Orf virus) genome.

Authors:  Michael J McGuire; Stephen A Johnston; Kathryn F Sykes
Journal:  Proteome Sci       Date:  2012-01-13       Impact factor: 2.480

8.  Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Authors:  Andrea Worschech; Nanhai Chen; Yong A Yu; Qian Zhang; Zoltan Pos; Stephanie Weibel; Viktoria Raab; Marianna Sabatino; Alessandro Monaco; Hui Liu; Vladia Monsurró; R Mark Buller; David F Stroncek; Ena Wang; Aladar A Szalay; Francesco M Marincola
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

Review 9.  Therapeutic immunomodulation using a virus--the potential of inactivated orf virus.

Authors:  O Weber; A A Mercer; A Friebe; P Knolle; H-D Volk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-22       Impact factor: 5.103

10.  Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models.

Authors:  Daniela Paulsen; Andreas Urban; Andreas Knorr; Claudia Hirth-Dietrich; Angela Siegling; Hans-Dieter Volk; Andrew A Mercer; Andreas Limmer; Beatrix Schumak; Percy Knolle; Helga Ruebsamen-Schaeff; Olaf Weber
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.